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Abstract 
Cardiovascular disease (CVD) is the prime cause of death in industrialized countries, 
resulting from the progression of atherosclerotic lesions. An increased level of plasma 
cholesterol, particularly within low-density lipoproteins, is a principle risk factor, but 
also elevated triglycerides and low levels of high-density lipoprotein cholesterol. 
Recognition of dyslipidemia as a risk factor for CVD has led to an international 
consensus that anti-hyperlipidemic drug therapy is essential for the primary and 
secondary prevention in risk patients. HMG-CoA reductase inhibitors, i.e. statins, are 
the most common drugs used for this purpose, inhibiting the rate-limiting step in 
cholesterol biosynthesis. The medical significance of HMG-CoA reductase inhibitors 
have in recent years been expanded to include cholesterol-independent or "pleiotropic" 
vascular effects, including improvement of vascular endothelial function, inhibition of 
vascular smooth muscle cell proliferation and migration, anti-inflammatory actions, 
anti-oxidative effects or stabilization of vulnerable plaques. These effects have 
potential in the treatment of coronary artery disease in various settings, such as 
prevention of its onset as well as its progression. The major aim of this thesis was to 
contribute to the general knowledge about the pleiotropic effects of statins, particularly 
in relation to the vascular endothelium and to carcinogenesis.  
 
We found that fluvastatin at clinically relevant doses up-regulates transcription and 
translation of prostacyclin synthase and endothelial nitric oxide synthase in human 
vascular endothelial cells, associated with an increase in cellular production of 
prostacyclin (PGI2) and nitric oxide (NO), and induces rapid dilatation in isolated 
human arteries via contribution of endothelium derived factors like NO and PGI2. 
These results suggest beneficial effects of fluvastatin on endothelial maintenance in 
vivo and a protective role on the cardiovascular system, particularly at the level of 
vascular endothelium. We also show that simvastatin induces a potentially negative 
alteration of vascular endothelial cells both in vivo and in vitro. Exposure of clinically 
comparable concentrations of simvastatin led to decreased production and release of 
PGI2 in endothelial cells and to significantly increased urinary thromboxane A2 
(TXA2) levels in healthy volunteers, possibly resulting in a shift of the balance 
between PGI2 and TXA2, favoring the thromboxane pathway. Fluvastatin and 
simvastatin were also shown to have different impact on vascular endothelial oxidative 
stress status, both in cultivated endothelial cells and in healthy volunteers. Compared 
to simvastatin, fluvastatin seems beneficial both regarding expression of anti-oxidative 
stress enzymes and reactive oxygen species activity in vitro and anti-oxidative 
capacity in vivo. The suggested anti-carcinogenic properties of statins in relation to 
expression of the redox-active enzymes thioredoxin reductases (TrxR) were 
investigated in paper IV. We found that statin treatment decreases the hepatic 
expression of TrxR1 in humans and rats. In addition, the decreased TrxR1-levels were 
correlated with inhibited carcinogenesis in rat liver. The effect on TrxR1 levels might 
explain some of the anti-carcinogenic effects of statins.   
 
Overall, our results add to the conjecture that the impact on production of vascular 
active substances may be significantly different among the statins, and thus the 
consequences of statin exposure may not be drug class related but rather compound 
specific, highlighting the importance of more comparative studies where several 
statins are included. These findings add novel insight in the field of pleiotropic effects 
of statins and provide some insight for functional differences among statins.  
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